BiotechTube
Home/Pipeline/177Lu-PSMA-I&T

177Lu-PSMA-I&T

Prostate Cancer

Phase 3Active - Registrational Trial

Key Facts

Indication
Prostate Cancer
Phase
Phase 3
Status
Active - Registrational Trial
Company
PDRadiopharma

About PDRadiopharma

A Japanese radiopharmaceutical company developing targeted radionuclide therapies and diagnostics for cancer, with a lead program in prostate cancer.

View full company profile

Therapeutic Areas

Oncology

Other Prostate Cancer Drugs

DrugCompanyPhase
APVO442Aptevo TherapeuticsPreclinical
APVO452Aptevo TherapeuticsDiscovery
BIO 300Humanetics Corp.Not Specified
OpaganibRedHill BiopharmaPhase 2
MagSense™ PSMA Imaging AgentImagion BiosystemsPre‑clinical
Small-Molecule TherapeuticAIkido LabsPre-clinical
LeronlimabCytoDynPreclinical
CROES RegistryAngioDynamicsPost-Market Registry
Cannabics® PRST-33CNBX PharmaceuticalsDiscovery
HDP-103Heidelberg PharmaPreclinical
ENV105Kairos PharmaPhase 2
AI for Prostate CancerInvenio ImagingResearch